^
Association details:
| Biomarker: | CD8-H |
|---|---|
| Cancer: | Breast Cancer |
| Drug: | Herceptin (trastuzumab) (HER2 inhibitor) + Perjeta (pertuzumab) (HER2 dimerization inhibitor) |
| Direction: | Sensitive |
Evidence:
Source:
Title:
Predicting Pathological Complete Response in Neoadjuvant Dual Blockade With Trastuzumab and Pertuzumab in HER2 Gene Amplified Breast Cancer
Published date:
05/19/2022
Excerpt:
This retrospective study included 159 HER2-amplified patients with locally advanced breast cancer who received neoadjuvant trastuzumab, pertuzumab and chemotherapy....In univariate logistic regression analyses in the training set, the HER2/CEP17 ratio (OR=1.307, p=0.001, 95% CI: 1.117–1.530), HER2 copy number (OR=1.097, p=0.012, 95% CI: 1.021–1.180), and CD8 level (OR=1.072, p=0.024, 95% CI: 1.009–1.139) (Table 2) were better associated with pCR.
Secondary therapy:
Chemotherapy
DOI:
10.3389/fimmu.2022.877825
